Markets
BSE See NSE See 39,116.68
70.34 (0.18%)
collapse Related Readings collapse

Ind-Swift Laboratories - Pharma poised

By Kaustubh Ghotikar | 8/29/2011 4:12 PM Monday

Ind-Swift Laboratories (ISLL) is a pharma company with a turnover of Rs 1031 crore, that has been growing briskly at a three-year CAGR of 30.60% in topline and 41% in bottomline, respectively. It has good products and a robust product pipeline, has been aggressively focusing on new markets and continuously expanding capacities and is a direct beneficiary of patent expiry in the developed markets.

In addition to the factors stated above, the company has a consistent dividend history, and is still available at a market cap of just Rs 264 crore, or a PE of merely 2.46x. Surprising as this may seem, it is true, and in the current market scenario, it is definitely a good value pick. It makes ample sense to grab the scrip at its CMP of Rs 79.

ISLL is a manufacturer of Active Pharmaceutical Ingredients (APIs), and supplies to various domestic formulation companies and generic players across regulated and semi-regulated markets, with a focus on therapeutic segments such as antibiotics, cardiovasculars, antihistamines etc. Currently, 60% of its revenues come from India, while the balance 40% comes from Europe, Middle East, Asia Pacific and the US.

The company has a strong basket of 40 products. Clarithromycin is a major revenue contributor, bringing in about 18.76% of its sales. Along with it, Clopidogrel (at 4.18%), Menthol (10.29%), Atorvastatin (4.26%) and Fexofenadine (3.62%) together make up the top five products, and bring in 41.11% of the company’s total revenues. The balance 58.89% comes from other products.

There are reasons why we believe that ISLL should do well. The domestic formulation market continues to grow strongly at around 15-16% annually Also, the fact that the market continues to remain fragmented, with the largest market share for a pharma major standing at just around five%, presents huge growth opportunities for companies like ISLL.

The rise in patent expiry will further drive ISLL’s growth, as over the next few years, drugs worth over USD 99 billion are expected to go off patent. In fact, ISLL is already positioning itself as a primary supplier of APIs to generic players in the regulated markets, and is steadily increasing its presence in countries like US, Europe and Japan. The company has also entered into agreements with global players for the supply of blockbuster drugs to these markets on patent expiry.

Besides, with the firm’s facility being FDA-compliant, and with a robust product basket of 40 products and another 20 in the pipeline, ISLL is sweetly poised to benefit from the same. Preparing itself to cater to this demand better, ISLL has been continuously expanding its capacities, and has already spent around Rs 276 crore in the last four years. In fact, in this fiscal too, ISLL is going for a capex of Rs 180 crore, which would be funded through debt and equity. All this bodes well for ISLL, as it will help push its revenue growth further.

For Q1 FY12, ISLL's sales grew almost 41% to Rs 279.43 crore (Rs 198.6 crore), while profits increased by 17% to Rs 17.33 crore (Rs 14.86 crore). For FY12, the management expects revenues to touch Rs 1150 crore, while profits could be around Rs 110 crore. At these estimates, the scrip is available at a PE of 2.46x, which is quite low. With consistent dividends (FY11 dividend at Rs 1 per share on FV of Rs 10), it makes sense to grab the scrip with a one-year target of Rs 98.

 

Find More Articles on: Stock Recommendations, Fundamental Picks, DSIJ Magazine, Low Priced Scrip

news letter

More for the early bird.

Get the post-market reports and breakfast news right in your inbox. See latest »

DSIJ Mindshare

Markets may open with a gap-up riding on global optimism

Karan DSIJ / Article rating: 5.0

The outlook for the Indian markets is a gap-up opening on the back of optimism in the global markets. The US and China will restart trade negotiations to reach a deal, Also, the ECB President surprised the markets by hinting at more stimulus if needed. At the time of writing, the SGX Nifty was trading higher by 50 points at 11,762.

12345678910Last

Tiger Logistics topline to grow by 10%--buoyant over infra sector status to logistics sector

Tiger Logistics topline to grow by 10%--buoyant over infra sector status to logistics sector

Logistics sector will play a vital role in making the concept of ‘Make in India’ a success. This will be further aided by some of the recent steps taken by Government of India such as granting of infra sector status to logistics sector.

Best and worst Performing Sector Funds of Year 2017

Best and worst Performing Sector Funds of Year 2017

As the year-end has approached most of you are eager to know the mutual fund movers and shakers of the year 2017. Read on to find the performance of various sector dedicated funds.

Markets may start positive, but volatility likely due to F&O expiry

Markets may start positive, but volatility likely due to F&O expiry

The start of the F&O expiry day is likely to be in the green, but volatility may creep in with the progress of the session. The SGX Nifty suggests that the Nifty could open at 10,525 with gains of 32 points at the opening bell. 

Pidilite announces buyback of Rs 500 crore

Pidilite announces buyback of Rs 500 crore

The buyback offer comprises purchase of up to 50,00,000 equity shares. The buyback offer size comprises 0.975 per cent of the total paid-up equity capital of the company.

Bank Nifty drags markets to close in the red

Bank Nifty drags markets to close in the red

The late session fall in Bank Nifty changed the direction of the market, leading to a marginal fall in the benchmark indices. Bank Nifty yet again resisted at its multiple point downward sloping trendline level at 25733.

Six major underperforming MF schemes having higher expense ratios

Six major underperforming MF schemes having higher expense ratios

Mutual funds with a large size of assets under management (AUMs) are supposed to have lower expense ratios. However, there are schemes with large AUMs but having higher expense ratios and generating lower returns. 

Nifty Pharma supports market; Sun Pharma at bullish reversal

Nifty Pharma supports market; Sun Pharma at bullish reversal

Nifty Pharma index has come in as the healer in an otherwise sluggish market. Index has given a consolidation breakout at the 9420 level today and if the it sustains 9420, followed by 9628 on the upside, it has a long way to go.

Ten stocks close to their 52-week low

Ten stocks close to their 52-week low

Following stocks are close to their 52-week low as at 12.35 p.m. on December 27.

Ten stocks close to their 52-week high

Ten stocks close to their 52-week high

The markets on December 27 opened gap down. BSE Sensex is trading at 34,068.15, up by 57.54 points and the Nifty is trading at 10,539.45, up by 7.95 points.

Five stocks with selling interest

Five stocks with selling interest

Overall volumes in futures & options currently stand at 62.75 lakh contracts with a turnover of Rs. 5,19,204.72 crore.